Top Page
Curaleaf Holdings
(OTC:CURA)
Curaleaf Holdings (CURA) vs. iShares MSCI Canada ETF (EWC)
Curaleaf Holdings Business Overview & Revenue Model
Curaleaf Holdings Earnings Call Summary
Curaleaf Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.29B | 1.34B | 1.35B | 1.34B | 1.21B | 626.64M |
| Gross Profit | 625.61M | 639.25M | 614.45M | 579.03M | 687.59M | 390.51M |
| EBITDA | 220.14M | 233.14M | 238.76M | 220.97M | 278.98M | 128.59M |
| Net Income | -244.34M | -215.42M | -281.20M | -376.93M | -109.13M | -61.33M |
Balance Sheet | ||||||
| Total Assets | 2.92B | 2.95B | 3.10B | 3.41B | 3.11B | 2.39B |
| Cash, Cash Equivalents and Short-Term Investments | 102.27M | 93.03M | 91.82M | 163.18M | 299.33M | 73.54M |
| Total Debt | 843.02M | 853.82M | 883.55M | 931.91M | 652.40M | 577.71M |
| Total Liabilities | 1.98B | 1.96B | 1.93B | 2.01B | 1.44B | 1.01B |
| Stockholders Equity | 871.30M | 861.21M | 1.05B | 1.28B | 1.55B | 1.38B |
Cash Flow | ||||||
| Free Cash Flow | 49.54M | 64.42M | 5.05M | -91.96M | -205.92M | -113.92M |
| Operating Cash Flow | 136.37M | 162.57M | 75.26M | 46.40M | -33.96M | 12.36M |
| Investing Cash Flow | -87.48M | -93.83M | -78.69M | -228.62M | -163.97M | -197.11M |
| Financing Cash Flow | -37.76M | -54.24M | -67.02M | 50.54M | 424.80M | 224.08M |
Curaleaf Holdings Technical Analysis
Curaleaf Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | C$1.31B | 50.59 | 1.73% | ― | 31.72% | ― | |
| ― | C$1.89B | ― | -12.60% | ― | 4.92% | -64.84% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$393.48M | ― | -0.70% | ― | 28.42% | 48.33% | |
| ― | C$3.02B | ― | -24.93% | ― | -2.64% | 1.65% | |
| ― | $750.73M | ― | -10.02% | ― | -5.65% | 73.45% | |
| ― | C$608.85M | ― | -98.42% | ― | -4.24% | 55.82% |
Curaleaf Holdings Corporate Events
Curaleaf Holdings, Inc. has expanded its revolving credit facility with Needham Bank from $40 million to $100 million, marking the largest facility of its kind in the U.S. cannabis sector. This move reflects increased confidence from institutional lenders and is expected to enhance Curaleaf’s financial flexibility, support its strategic growth initiatives, and contribute to the broader acceptance of cannabis businesses in capital markets.
The most recent analyst rating on (TSE:CURA) stock is a Hold with a C$3.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.
On October 1, 2025, Curaleaf Holdings announced that its Executive Vice Chairman, Joseph F. Lusardi, established an automatic securities disposition plan (ASDP) effective September 30, 2025. This plan allows for the orderly exercise of options expiring in March 2026 and the sale of subordinate voting shares to cover taxes. The ASDP is designed to comply with U.S. and Canadian securities laws, enabling insiders to sell shares without possessing material undisclosed information. The sales will be conducted by an independent broker, with restrictions on Mr. Lusardi’s influence over the process, and will be reported in accordance with securities laws.
The most recent analyst rating on (TSE:CURA) stock is a Hold with a C$3.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.
Curaleaf Holdings announced the establishment of an automatic securities disposition plan (ASDP) by its Executive Vice Chairman, Joseph F. Lusardi, to facilitate the orderly exercise of options expiring in March 2026 and the sale of some subordinate voting shares to cover taxes. This plan, compliant with U.S. and Canadian securities laws, allows insiders to sell shares according to pre-arranged instructions, ensuring transparency and compliance. The ASDP will be executed by an independent broker, with sales commencing in January 2026, potentially impacting the company’s stock liquidity and insider trading transparency.
The most recent analyst rating on (TSE:CURA) stock is a Hold with a C$3.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.
Curaleaf Holdings announced it will release its third-quarter 2025 financial and operational results on November 5, 2025, after market close. The announcement will be followed by a conference call and audio webcast, providing insights into the company’s operational and financial highlights. This release is significant for stakeholders as it offers an opportunity to gauge Curaleaf’s performance and strategic direction in the evolving cannabis market.
The most recent analyst rating on (TSE:CURA) stock is a Hold with a C$3.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.
Curaleaf Holdings, Inc. announced its inclusion in the S&P/TSX Composite Index under the Health Care sector, effective September 22, 2025. This milestone positions Curaleaf as the first U.S.-based cannabis operator in the index, enhancing its visibility and credibility in North American capital markets. The inclusion is seen as a pivotal moment for the company and the broader cannabis industry, reflecting growing legitimacy and long-term potential. It also expands Curaleaf’s access to institutional investment and index-linked vehicles, supporting its ongoing development and potential regulatory advancements.
The most recent analyst rating on (TSE:CURA) stock is a Hold with a C$3.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.
Curaleaf Holdings, Inc. has been included in the S&P/TSX Composite Index under the Health Care sector, marking a significant milestone as the first U.S.-based cannabis operator to join this prestigious index. This inclusion enhances Curaleaf’s visibility and credibility in North American capital markets, potentially increasing its access to institutional investments and index-linked vehicles, thereby supporting its growth and development in the evolving cannabis industry.
The most recent analyst rating on (TSE:CURA) stock is a Hold with a C$3.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.
Curaleaf Holdings’ recent earnings call painted a picture of mixed sentiments. While the company celebrated significant growth in its international markets, driven by strategic investments and innovative product launches, it also faced domestic challenges. Revenue declines and pricing pressures in the U.S. were notable hurdles. Despite these issues, Curaleaf expressed optimism about future growth opportunities and potential regulatory reforms.
Curaleaf Holdings, Inc. is a leading international provider of consumer cannabis products, known for its quality and innovation, with operations spanning 17 U.S. states and 15 countries worldwide. In its second quarter of 2025, Curaleaf reported a total revenue of $315 million, marking a 1.5% increase from the previous quarter, and highlighted its expansion into Turkey’s medical cannabis market. The company achieved an adjusted gross margin of 49% and generated $66 million in adjusted EBITDA, reflecting a 21% margin, despite a year-over-year revenue decrease of 8%. Curaleaf’s international segment showed robust growth with a 62% increase in revenue compared to the previous year. The company also opened new retail locations and launched innovative products, further strengthening its market presence. Looking ahead, Curaleaf aims to capitalize on emerging opportunities by focusing on product quality and customer service, positioning itself for continued growth in the evolving cannabis industry.
Curaleaf Holdings reported a second-quarter 2025 revenue of $315 million, with a notable 62% year-over-year growth in its international segment. The company was awarded a license to operate in Turkey, marking a significant expansion in its international operations. Despite a net loss, Curaleaf is focusing on strategic growth, including opening new retail locations, launching innovative products, and strengthening its leadership team to position itself for future industry growth.
The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.